AVXS-101 (Zolgensma®) to be made available globally through a controversial programme

The biotechnology company Avexis, a wholly owned subsidiary of Novartis, has recently announced the launch of a global managed-access programme (MAP) for its gene therapy product AVXS-101. Under the programme, Avexis intends to make a limited number of AVXS-101 packages available at no cost for use in countries where the drug has not yet received … Continue reading AVXS-101 (Zolgensma®) to be made available globally through a controversial programme